Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > News > Octoplus and Cytimmune give anticancer drug TNF new chance

May 28th, 2003

Octoplus and Cytimmune give anticancer drug TNF new chance

Abstract:
OctoPlus and CytImmune Sciences, Inc., announced today that they have entered into a collaboration agreement to develop a novel treatment for solid cancers. The treatment's active agent is the anticancer protein, tumor necrosis factor (TNF). (see 2nd story)

Source:
Octoplus

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

High-tech 'paint' could spare patients repeated surgeries March 8th, 2024

Researchers develop artificial building blocks of life March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project